Bausch + Lomb (BLCO) Stock Forecast & Price Target

$20.63

-0.30 (-1.43%)

(As of 10/18/2024 ET)

Bausch + Lomb - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
5

Buy
7

Based on 12 Wall Street analysts who have issued ratings for Bausch + Lomb in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 5 have given a hold rating, and 7 have given a buy rating for BLCO.

Consensus Price Target

$20.00
-3.05% Downside

According to the 12 analysts' twelve-month price targets for Bausch + Lomb, the average price target is $20.00. The highest price target for BLCO is $25.00, while the lowest price target for BLCO is $17.00. The average price target represents a forecasted downside of -3.05% from the current price of $20.63.

BLCO Analyst Ratings Over Time

Type	Current Forecast 10/22/23 to 10/21/24	1 Month Ago 9/22/23 to 9/21/24	3 Months Ago 7/24/23 to 7/23/24	1 Year Ago 10/22/22 to 10/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)	4 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$20.00	$18.59	$18.95	$20.23
Forecasted Upside	-3.05% Downside	-6.86% Downside	11.30% Upside	19.62% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

BLCO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BLCO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bausch + Lomb Stock vs. The Competition

Type	Bausch + Lomb	Medical Companies	S&P 500
Consensus Rating Score	2.58	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	-3.05% Downside	13,587.63% Upside	6.20% Upside
News Sentiment Rating	Positive News See Recent BLCO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/15/2024	Evercore ISI 2 of 5 stars	V. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$19.00 ➝ $25.00	+19.90%
9/23/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$19.00 ➝ $22.00	+11.51%
9/23/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Hold ➝ Hold	$16.00 ➝ $19.00	-4.81%
9/16/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
8/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$14.00 ➝ $18.00	+4.05%
8/1/2024	Evercore Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line	$15.50 ➝ $17.00	-1.85%
Man behind OpenAI makes shocking new bet (Ad) Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously. Check out our report right here.
8/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $20.00	+13.64%
7/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Nachman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00	+23.94%
5/6/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$16.00 ➝ $18.00	+32.35%
2/26/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $18.00	+2.27%
2/22/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$21.00 ➝ $23.00	+35.06%
12/12/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$23.00 ➝ $21.00	+40.94%
8/3/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$22.00 ➝ $25.00	+34.48%
7/3/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$19.00 ➝ $23.00	+14.60%
2/23/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$15.00 ➝ $17.00	-6.64%
11/23/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Amit Hazan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral	$19.00 ➝ $17.00	+14.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:00 AM ET.

BLCO Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Bausch + Lomb is $20.00, with a high forecast of $25.00 and a low forecast of $17.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BLCO shares.
: According to analysts, Bausch + Lomb's stock has a predicted downside of -3.05% based on their 12-month stock forecasts.
: Over the previous 90 days, Bausch + Lomb's stock had 1 upgrade by analysts.
: Bausch + Lomb has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Evercore, Evercore ISI, HC Wainwright, Needham & Company LLC, Royal Bank of Canada, and Stifel Nicolaus in the past 90 days.
: Analysts like Bausch + Lomb less than other "medical" companies. The consensus rating score for Bausch + Lomb is 2.58 while the average consensus rating score for "medical" companies is 2.79. Learn more on how BLCO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

This page (NYSE:BLCO) was last updated on 10/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Bausch + Lomb (BLCO) Stock Forecast & Price Target